Taken together, our findings thus determined that WDR5 not only regulates tumor-cell immunogenicity to inhibit tumor growth but also stimulates immune suppressive pathways to promote tumor immune escape from host immune surveillance, providing the rationale for the selective targeting WDR5-MHC I pathway and/or WDR5-immune checkpoint/cytokine pathways, respectively, in WDR5-based epigenetic tumor immunotherapy. The gene discussed is WDR5; the disease is neoplasm.